PMID- 23382938
OWN - NLM
STAT- MEDLINE
DCOM- 20130801
LR  - 20231213
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 1
DP  - 2013
TI  - Prognostic significance of the combined score of endothelial expression of 
      nucleolin and CD31 in surgically resected non-small cell lung cancer.
PG  - e54674
LID - 10.1371/journal.pone.0054674 [doi]
LID - e54674
AB  - Nucleolin is implicated to play a role in angiogenesis, a vital process in tumor 
      growth and metastasis. However, the presence and clinical relevance of nucleolin 
      in human non small cell lung cancer (NSCLC) remains largely unknown. In this 
      study, we explored the expression and prognostic implication of nucleolin in 
      surgically resected NSCLC patients. A cohort of 146 NSCLC patients who underwent 
      surgical resection was selected for tissue microarray. In this tissue microarray, 
      nucleolin expression was measured by immunofluorescence. Staining for CD31, a 
      marker of endothelial cells, was performed to mark blood vessels. A Cox 
      proportional hazards model was used to assess the prognostic significance of 
      nucleolin. Nucleolin expression was observed in 34.2% of all patients, and 64.1% 
      in high CD31 expression patients. The disease-free survival (DFS) was 
      significantly shorter in patients with high nucleolin (CD31(hi)NCL(hi)) compared 
      to patients with low tumor blood vessels (CD31(lo)NCL(lo)) (5 ys of DFS 24% vs 
      64%, p = 0.002). Such a difference was demonstrated in the following stratified 
      analyses: stage I (p<0.001), squamous cell carcinoma and adenosquamous cell 
      carcinoma (p = 0.028), small tumor (<5 cm, p = 0.008), and surgery alone (p = 
      0.015). Multivariate analysis further revealed that nucleolin expression 
      independently predicted for worse survival (p = 0.003). This study demonstrates 
      that nucleolin is associated with the clinical outcomes in postoperative NSCLC 
      patients. Thus, the expression levels of nucleolin may provide a new prognostic 
      marker to identify patients at higher risk for treatment failure, especially in 
      some subgroups.
FAU - Zhao, Hongyun
AU  - Zhao H
AD  - State Key Laboratory of Oncology in South China, Cancer Center, Sun Yat-Sen 
      University, Guangzhou, China.
FAU - Huang, Yan
AU  - Huang Y
FAU - Xue, Cong
AU  - Xue C
FAU - Chen, Yang
AU  - Chen Y
FAU - Hou, Xue
AU  - Hou X
FAU - Guo, Ying
AU  - Guo Y
FAU - Zhao, Liping
AU  - Zhao L
FAU - Hu, Zhi huang
AU  - Hu Zh
FAU - Huang, Yujie
AU  - Huang Y
FAU - Luo, Yongzhang
AU  - Luo Y
FAU - Zhang, Li
AU  - Zhang L
LA  - eng
PT  - Journal Article
DEP - 20130131
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Phosphoproteins)
RN  - 0 (Platelet Endothelial Cell Adhesion Molecule-1)
RN  - 0 (RNA-Binding Proteins)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Biomarkers, Tumor
MH  - Bone Neoplasms/secondary
MH  - Carcinoma, Non-Small-Cell Lung/*metabolism/mortality/pathology/surgery
MH  - Endothelial Cells/*metabolism
MH  - Female
MH  - Humans
MH  - Lung Neoplasms/*metabolism/mortality/pathology/surgery
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Phosphoproteins/*metabolism
MH  - Platelet Endothelial Cell Adhesion Molecule-1/*metabolism
MH  - Prognosis
MH  - Proportional Hazards Models
MH  - RNA-Binding Proteins/*metabolism
MH  - Nucleolin
PMC - PMC3561357
COIS- Competing Interests: The authors have declared that no competing interests exist.
EDAT- 2013/02/06 06:00
MHDA- 2013/08/02 06:00
PMCR- 2013/01/31
CRDT- 2013/02/06 06:00
PHST- 2012/07/16 00:00 [received]
PHST- 2012/12/17 00:00 [accepted]
PHST- 2013/02/06 06:00 [entrez]
PHST- 2013/02/06 06:00 [pubmed]
PHST- 2013/08/02 06:00 [medline]
PHST- 2013/01/31 00:00 [pmc-release]
AID - PONE-D-12-20799 [pii]
AID - 10.1371/journal.pone.0054674 [doi]
PST - ppublish
SO  - PLoS One. 2013;8(1):e54674. doi: 10.1371/journal.pone.0054674. Epub 2013 Jan 31.